Current status of the small molecule anti-HIV drugs in the pipeline or recently approved

化学 小分子 人类免疫缺陷病毒(HIV) 药理学 立体化学 组合化学 病毒学 生物化学 医学 生物
作者
T. Umumararungu,Jean Baptiste Nyandwi,Jonathan Katandula,Eric Twizeyimana,JC Tomani,Noël Gahamanyi,Nestor Ishimwe,Emmanuel O. Olawode,Gratien Habarurema,Matabishi Mpenda,Jeanne Primitive Uyisenga,Sahar Saeed
出处
期刊:Bioorganic & Medicinal Chemistry [Elsevier]
卷期号:: 117860-117860
标识
DOI:10.1016/j.bmc.2024.117860
摘要

Human Immunodeficiency Virus (HIV) is the causative agent of Acquired Immunodeficiency Syndrome (AIDS) with high morbidity and mortality rates. Treatment of AIDS/HIV is being complicated by increasing resistance to currently used antiretroviral (ARV) drugs, mainly in low- and middle-income countries (LMICs) due to drug misuse, poor drug supply and poor treatment monitoring. However, progress has been made in the development of new ARV drugs, targeting different HIV components (Fig. 1). This review aims at presenting and discussing the progress made towards the discovery of new ARVs that are at different stages of clinical trials as of July 2024. For each compound, the mechanism of action, target biomolecule, genes associated with resistance, efficacy and safety, class, and phase of clinical trial are discussed. These compounds include analogues of nucleoside reverse transcriptase inhibitors (NRTIs) - islatravir and censavudine; non-nucleoside reverse transcriptase inhibitors (NNRTIs) - Rilpivirine, elsulfavirine and doravirine; integrase inhibitors namely cabotegravir and dolutegravir and chemokine coreceptors 5 and 2 (CC5/CCR2) antagonists for example cenicriviroc. Also, fostemsavir is being developed as an attachment inhibitor while lenacapavir, VH4004280 and VH4011499 are capsid inhibitors. Others are maturation inhibitors such as GSK-254, GSK3532795, GSK3739937, GSK2838232, and other compounds labelled as miscellaneous (do not belong to the classical groups of anti-HIV drugs or to the newer classes) such as obefazimod and BIT225. There is a considerable progress in the development of new anti-HIV drugs and the effort will continue since HIV infections has no cure or vaccine till now. Efforts are needed to reduce the toxicity of available drugs or discover new drugs with new classes which can delay the development of resistance.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sky完成签到,获得积分10
1秒前
1秒前
1秒前
美丽的楼房完成签到 ,获得积分10
2秒前
Ziyi_Xu完成签到,获得积分10
3秒前
1230完成签到,获得积分20
3秒前
chuyue发布了新的文献求助10
4秒前
略略略发布了新的文献求助10
4秒前
北地风情完成签到 ,获得积分10
4秒前
认真的AG发布了新的文献求助10
4秒前
6秒前
杨锋发布了新的文献求助10
6秒前
Owen应助123采纳,获得10
6秒前
7秒前
7秒前
7秒前
ttm1983完成签到,获得积分10
8秒前
Chufis发布了新的文献求助10
9秒前
乐观的非笑完成签到,获得积分10
9秒前
9秒前
我是老大应助小木采纳,获得30
10秒前
lala完成签到,获得积分10
11秒前
顺宏冉呀发布了新的文献求助10
11秒前
12秒前
1234发布了新的文献求助10
13秒前
14秒前
14秒前
14秒前
15秒前
qiuqiu120234978完成签到,获得积分10
16秒前
123完成签到,获得积分20
16秒前
酷炫的秋凌完成签到 ,获得积分10
17秒前
17秒前
上官若男应助科研通管家采纳,获得10
17秒前
情怀应助科研通管家采纳,获得10
17秒前
小马甲应助科研通管家采纳,获得10
17秒前
科目三应助科研通管家采纳,获得10
18秒前
18秒前
小纯洁发布了新的文献求助10
18秒前
酷波er应助科研通管家采纳,获得10
18秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3146272
求助须知:如何正确求助?哪些是违规求助? 2797641
关于积分的说明 7825012
捐赠科研通 2454032
什么是DOI,文献DOI怎么找? 1305957
科研通“疑难数据库(出版商)”最低求助积分说明 627630
版权声明 601503